Form 4: Acadia Pharma Officer Sells Shares for Tax

Acadia Pharmaceuticals' Principal Accounting Officer, James Kihara, sold shares to cover tax obligations following restricted stock unit vesting.

Summary

• James Kihara, Principal Accounting Officer of ACADIA PHARMACEUTICALS INC, reported transactions involving the company's common stock.
• On November 17, 2025, Kihara acquired 3,966 shares of common stock through the vesting of restricted stock units (RSUs).
• Also on November 17, 2025, an additional 3,966 shares of common stock were acquired through RSU vesting.
• On November 18, 2025, Kihara sold 4,084 shares of common stock at a weighted average price of $23.6909 per share.
• The sale was mandatory and intended to cover withholding taxes and tax-related items associated with the RSU vesting, structured under a Rule 10b5-1(c) plan.
• The reported price of $23.6909 is a weighted average, with shares sold in multiple transactions ranging from $23.69 to $23.80.
• Following these transactions, Kihara beneficially owns 25,058 shares of common stock directly.
• The beneficial ownership also includes 815 shares acquired on November 14, 2025, through an employee stock purchase plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as this is a routine, pre-planned insider transaction primarily for tax purposes, which does not reflect a discretionary investment decision or new information about the company's performance.

Positives

• The vesting of restricted stock units indicates continued employment and performance-based compensation for a key executive.
• Participation in the employee stock purchase plan (ESPP) suggests confidence in the company's long-term prospects by an insider.

Negatives

• A portion of the shares acquired through RSU vesting was immediately sold, reducing the insider's direct equity stake, although this was for tax purposes.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing details a routine insider transaction for tax purposes, which is common across all industries, particularly for executives receiving equity compensation. It does not provide specific insights into broader industry trends or competitive positioning for Acadia Pharmaceuticals.

Stakeholder Impact

• Shareholders: The transaction is a routine tax-related sale by an insider and is unlikely to have a significant direct impact on shareholder value or perception.
• Employees: The vesting of RSUs and participation in an ESPP are standard components of employee compensation, indicating ongoing incentive alignment.

Key Dates

Recommendation

This Form 4 filing reports a routine, pre-scheduled insider transaction for tax purposes following RSU vesting. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals rather than this specific insider transaction.

Keywords

ACADIA PHARMACEUTICALS, ACAD, James Kihara, Form 4, Insider Trading, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Employee Stock Purchase Plan, ESPP